YIV-906 enhances nuclear factor of activated T-cells (NFAT) activity of T cells and promotes immune checkpoint blockade antibody action and CAR T-cell activity

YIV-906 is a systems biology botanical cancer drug, inspired by a traditional Chinese herbal formulation. Results from eight Phase I/II to II clinical studies demonstrated the potential of YIV-906 to prolong survival and improve the quality of life of cancer patients. As an immunomodulator in the tumor microenvironment, YIV-906 can turn cold tumors hot and potentiate anti-tumor activity for different classes of anticancer agents; and as a cytoprotector in the GI, YIV-906 can reduce non-hematological side effects and speed up damaged tissue recovery. YIV-906 enhanced anti-PD1 action against hepatoma in mice by stimulating both innate and adaptive immunity. In a Jurkat cell-staphylococcal superantigen E (SEE)-Raji cell culture model, YIV-906 promoted T cell activation with upregulation of CD69 by enhancing NFAT activity, with or without PD1-PD-L1 interaction. YIV-906 could trigger the phosphorylation of TCR downstream signaling cascades without the involvement of TCR. YIV-906 could inhibit SHP1 and SHP2 activities, which dephosphorylates TCR downstream proteins due to the PD1-PD-L1 interaction. Therefore, YIV-906 could enhance anti-PD1 action to rescue the depressed NFAT activity of Jurkat cells due to the PD1-PD-L1 interaction. In addition, YIV-906 enhanced the NFAT activity and killing capability of Jurkat cells expressing chimeric antigen receptor (CAR-CD19−CD3z) toward CD19 expressing cells, such as Raji cells, with or without PD1-PD-L1 overexpression. Ingredient herb S (Scutellaria baicalensis Georgi) of YIV-906 and some S compounds were found to play key roles in these activities. In conclusion, YIV-906 modulates adaptive immunity by activating T effector cells mainly through its action on SHP1/2. YIV-906 could also facilitate immune checkpoint blockade therapy or CAR-T cell therapy for cancer treatment.

[1]  Caroline H. Johnson,et al.  YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment , 2021, Scientific Reports.

[2]  P. Gibbs,et al.  Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. , 2020, The New England journal of medicine.

[3]  Y. Yen,et al.  A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma , 2020, The oncologist.

[4]  M. Goldsmith,et al.  Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity , 2020, Frontiers in Immunology.

[5]  Huibin Zhang,et al.  Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application. , 2020, Journal of medicinal chemistry.

[6]  Leo D. Wang,et al.  Chimeric antigen receptor signaling: Functional consequences and design implications , 2020, Science Advances.

[7]  G. Freeman,et al.  Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation , 2020, Communications Biology.

[8]  W. Schamel,et al.  Molecular mechanism of SHP2 activation by PD-1 stimulation , 2020, Science Advances.

[9]  M. Kudo,et al.  Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Shuo Wang,et al.  Multifunctional biomimetic nanoparticles loading baicalin for polarizing tumor-associated macrophages. , 2019, Nanoscale.

[11]  Junmei Wang,et al.  New application of in silico methods in identifying mechanisms of action and key components of anti-cancer herbal formulation YIV-906 (PHY906). , 2019, Physical chemistry chemical physics : PCCP.

[12]  R. Aebersold,et al.  Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy , 2019, Cell reports.

[13]  Wing Lam,et al.  Mechanism Based Quality Control (MBQC) of Herbal Products: A Case Study YIV-906 (PHY906) , 2018, Front. Pharmacol..

[14]  Qiang Xu,et al.  SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade , 2018, Acta pharmaceutica Sinica. B.

[15]  L. Chekir‐Ghedira,et al.  Chrysin, a natural and biologically active flavonoid suppresses tumor growth of mouse B16F10 melanoma cells: In vitro and In vivo study. , 2018, Chemico-biological interactions.

[16]  L. Chekir‐Ghedira,et al.  Immunomodulatory potential of hesperetin and chrysin through the cellular and humoral response , 2017, European journal of pharmacology.

[17]  J. Desai,et al.  Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. , 2017, The Lancet. Oncology.

[18]  M. Kudo,et al.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial , 2017, The Lancet.

[19]  Sheela Chandra,et al.  Flavonoids: an overview , 2016, Journal of Nutritional Science.

[20]  Xiao-Bin Jia,et al.  Inhibition of Tumor Growth and Immunomodulatory Effects of Flavonoids and Scutebarbatines of Scutellaria barbata D. Don in Lewis-Bearing C57BL/6 Mice , 2015, Evidence-based complementary and alternative medicine : eCAM.

[21]  Hongyu Zhao,et al.  PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment , 2015, Scientific Reports.

[22]  Razelle Kurzrock,et al.  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.

[23]  Edward Chu,et al.  The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018) , 2014, BMC Complementary and Alternative Medicine.

[24]  M. Saif,et al.  First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer , 2014, Cancer Chemotherapy and Pharmacology.

[25]  S. Rockwell,et al.  Preclinical studies of the Chinese Herbal Medicine formulation PHY906 (KD018) as a potential adjunct to radiation therapy , 2013, International journal of radiation biology.

[26]  Shwu-Huey Liu,et al.  Old formula, new Rx: the journey of PHY906 as cancer adjuvant therapy. , 2012, Journal of ethnopharmacology.

[27]  C. Ware,et al.  The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation , 2011, Immunological reviews.

[28]  Mark O'Rourke,et al.  A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer. , 2011, Clinical colorectal cancer.

[29]  Wei Zhang,et al.  Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS). , 2010, Journal of chromatography. A.

[30]  Jeffrey Bjoraker,et al.  A comprehensive platform for quality control of botanical drugs (PhytomicsQC): a case study of Huangqin Tang (HQT) and PHY906 , 2010, Chinese medicine.

[31]  Yung-chi Cheng,et al.  The Four-Herb Chinese Medicine PHY906 Reduces Chemotherapy-Induced Gastrointestinal Toxicity , 2010, Science Translational Medicine.

[32]  N. Grant,et al.  Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies. , 2010, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[33]  Y. Yen,et al.  Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. , 2009, Anticancer research.

[34]  U. Lorenz,et al.  SHP‐1 and SHP‐2 in T cells: two phosphatases functioning at many levels , 2009, Immunological reviews.

[35]  Yung-chi Cheng,et al.  Liquid chromatography/mass spectrometry analysis of PHY906, a Chinese medicine formulation for cancer therapy. , 2007, Rapid communications in mass spectrometry : RCM.

[36]  C. June,et al.  SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1 , 2004, The Journal of Immunology.